TBC1D4

Across TCGA pan-cancer cohorts, TBC1D4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D4 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher TBC1D4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCS, UCEC, and KIRP are the cancer types where TBC1D4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.001	0.690	<.001	36	view →
UCEC	DFS	Median	All	0.952	0.609	.001	36	view →
KIRP	OS	Median	II,III,IV	0.141	0.772	<.001	24	view →
CESC	OS	Median	All	0.105	0.587	.016	12	view →
SKCM	DFS	Median	All	1.000	0.717	.015	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D4–UCS (OS)

Open the UCS breakdown →